Aprea reports preliminary cash of $26.2M; CMO Mirza steps down, engages Dr. Pultar as advisor

Aprea Therapeutics, Inc.

Preliminary cash and equivalents ~$26.2M as of Sep 30, 2024, down from $28.7M at Jun 30, 2024.
Dr. Nadeem Mirza steps down as CMO effective Oct 9, 2024; will remain through Dec 13, 2024.
Engaged Dr. Philippe Pultar as Senior Medical Advisor to lead WEE1 inhibitor APR-1051 Phase 1 trial.
Patient enrollment ongoing in Phase 1 ACESOT-1051 study for APR-1051; update expected by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.